(MENAFN- Trend News Agency) Health Canada on Thursday authorized an adapted version of the
Moderna Spikevax COVID-19 vaccine that targets the Omicron
BA.4/BA.5 subvariants, reports citing .
Health Canada approved the bivalent vaccine for use as a booster
dose in individuals 18 years of age or older, saying that clinical
trial results showed it triggers a strong immune response against
both Omicron (BA.4/BA.5) and the original SARS-CoV-2 virus
strains.
This adapted vaccine has a similar safety profile to the
previously approved Moderna Spikevax boosters, with the same mild
adverse reactions that resolved quickly, Health Canada said.
Keeping COVID-19 vaccinations up-to-date, including getting
booster doses as recommended, will help protect an individual
against serious illness and other complications of COVID-19
infection, Health Canada said.
The number of total COVID-19 cases and deaths in Canada reached
4,336,860 and 46,389 respectively, according to the weekly update
issued by the Public Health Agency of Canada (PHAC) last week.
MENAFN03112022000187011040ID1105130119
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.